Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator.
## Primary Indications
* Treatment of peripheral vascular diseases, such as intermittent claudication.
* Adjunctive therapy in cerebrovascular insufficiency.
## Adult Dosing
* **Oral:** 10 mg to 20 mg three to four times daily.
* **Maximum Dose:** No specific maximum dose is established, but doses higher than 20 mg per administration are generally not recommended.
## Pediatric Dosing
* Data is insufficient to establish pediatric dosing.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Should not be administered intravenously in cases of congenital heart disease or when a rapid blood pressure fall is undesirable.
## Adverse Effects
* **Common:** Hypotension, dizziness, flushing, gastrointestinal upset (nausea, vomiting, abdominal distress), weakness, nervousness, rash.
* **Serious:** Cardiac arrhythmias, chest pain, severe hypotension.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the hypotensive effects of antihypertensive medications.
* **Sympathomimetic agents:** Concurrent use may lead to additive cardiovascular effects.
## Monitoring
* Blood pressure.
* Symptoms of peripheral vascular disease (e.g., pain, walking distance).
* Signs of adverse effects.
## Clinical Pearls
* Effectiveness in peripheral vascular disease is controversial, and it is not a first-line therapy.
* Ensure patients are aware of potential dizziness and the importance of rising slowly from a seated or lying position.
---
*This information is for educational purposes only and does not substitute for professional medical advice. Always consult the current prescribing information and a qualified healthcare provider for any medical condition or treatment. Dosing and recommendations may vary based on individual patient factors and local protocols.*